Kazia Therapeutics Ltd

NV9

Company Profile

  • Business description

    Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

  • Contact

    300 Barangaroo Avenue
    Level 24
    Three International Towers
    SydneyNSW2000
    AUS

    T: +61 294724101

    E: investment.consultant@novogen.com

    https://www.kaziatherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

    7

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,637.8012.900.15%
CAC 407,779.728.38-0.11%
DAX 4023,933.23104.96-0.44%
Dow JONES (US)42,047.1351.57-0.12%
FTSE 1008,716.459.56-0.11%
HKSE23,573.38315.071.35%
NASDAQ19,199.1698.220.51%
Nikkei 22538,432.98710.581.88%
NZX 50 Index12,281.3180.95-0.65%
S&P 5005,903.2414.690.25%
S&P/ASX 2008,409.8012.900.15%
SSE Composite Index3,363.4523.510.70%

Market Movers